Mattias Svensson

Mattias Svensson

Principal Researcher | Docent
Visiting address: Alfred Nobels allé 8, plan 7, 14152 Huddinge
Postal address: H7 Medicin, Huddinge, H7 CIM Svensson, 171 77 Stockholm
Part of:

About me

  • Expertise in preclinical research in the field of immunology and infection,
    myeloid immune cells, host pathogen interactions and cell biology.
    Conduct translational projects based on preclinical science. 
    Particular interest: Infection and immunology, as well as in fibroblasts, human myeloid 
    immune cells such as monocytes, dendritic cells and macrophages in acute and
    chronic tissue inflammation.
    Current position: Research group leader, associate professor.
    Is Director of Doctoral Education at the Department of Medicine, Huddinge and
    Chairman of the Dissertation Committee at Karolinska Institutet.
    1995, MSc, Biology, Lund University, Sweden
    2000, PhD, Immunology, Lund University, Sweden
    2001-2004, Post doctoral Fellow, London School of Hygiene and Tropical
    Medicin, London, UK
    2010, Associate Professor, Immunology, Karolinska Institutet, Sweden

Research

  • Our research group [1] at the Center for Infectious Medicine (CIM [2]),
    Department of Medicine, Huddinge conducts research aimed at understanding how
    the tissue microenvironment influences the development and function of myeloid immune cellsin homeostasis, infection and chronic inflammatory conditions. In particular the focus is on the ability of tissue-specific cells, especially fibroblasts, to shape the function of myeloid cells. 
    We strive to identify proteins and metabolites that are important for
    tissue-specific cells, such as fibroblasts, to shape the microenvironment for
    the function of myeloid immune cells and the specific properties of bacteria.
    The goal is to:
    1. Develop customized human organotypic models for homeostasis and disease mechanism 
    identification, biomarker detection, and validation of interventions in infection and inflammatory disease.
    2. Utilize identified disease mechanisms to develop tailored therapy and
    implement personalized medicine in sever infectious diseases caused by bacteria
    3. Identify central host-derived mediators which in the tissue environment influences the development and function of human myeloid immune cells. 
    [1] https://ki.se/en/medh/mattias-svensson-group-studies-of-tissue-microbiology-and-immunology
    [2] https://ki.se/en/medh/center-for-infectious-medicine-cim

Articles

All other publications

Grants

  • Swedish Research Council
    1 January 2024 - 31 December 2026
    The biological importance of fibroblasts is undisputed. However, in depth fibroblast characterization on protein level in situ and ex vivo, as well their functional relationship with immune cells, such as macrophages, in microanatomical niches do not exist today. Macrophages are found in all tissues, and are important for tissue homeostasis, as well as in controlling infection and inflammation. We hypothesize that the contrasting functions of macrophages in tissue might be linked to tissue and context dependent modulation through fibroblasts. Our preliminary data indicate that (PDGFRA+CD142-) fibroblasts co-localize with monocytes/macrophages in human inflamed and non-inflamed intestine. Through access to organ donor tissue and well-characterized patient samples, as well as cutting edge single cells RNA sequencing, multiparameter flow cytometry, and novel ultra-high content imaging technologies combined with advanced in-house developed cell culture-systems, we will (1) investigate transcriptional fibroblast heterogeneity across and within human tissue (2) validate transcriptional data at protein and cellular levels, and (3) investigate the conditions and prerequisites for fibroblasts shaping the macrophage pool. The proposed research has the potential to provide new mechanistical insights into tissue homeostasis, inflammation, and resolution, as well as into fibroblast functions which can be explored in novel therapeutic approaches targeting fibroblasts in disease.
  • Assays for acceleration: from fit-for-purpose models to scalable assays of broad systemic and mucosal protection against all strains of Group A Streptococcus
    National Institutes of Health
    1 January 2023 - 31 December 2025
  • Swedish Research Council
    1 January 2019 - 31 July 2019
  • Swedish Research Council
    1 January 2014 - 31 December 2017
  • Swedish Research Council
    1 January 2010 - 31 December 2012
  • Swedish Research Council
    1 January 2010 - 31 December 2012
  • Swedish Research Council
    1 January 2009 - 31 December 2009

Employments

  • Principal Researcher, Department of Medicine, Huddinge, Karolinska Institutet, 2022-

Degrees and Education

  • Docent, Karolinska Institutet, 2010

News from KI

Events from KI